Pacific Biosciences of California, Inc. announced that GrandOmics Biosciences Co. Ltd. of Beijing, through its subsidiary NextOmics in Wuhan, has agreed to purchase five additional Sequel™ instruments to support China’s precision medicine initiative, with a specific focus on ultimately providing the genetic diagnosis of inherited diseases. GrandOmics was one of the early commercial sequencing service providers in China to purchase a Sequel System, and previously provided services for de novo genome assembly and full-length transcriptome analysis based on their bioinformatics expertise using the PacBio® RS II system. Both instruments are based on PacBio’s Single Molecule, Real-Time (SMRT®) Sequencing technology.